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Background 
Increasing resistance of Gram-negative bacteria 
isolated from nosocomial infections and chronic 
wounds, such as diabetic foot ulcers has renewed 
research interests in the use of polymyxins in the 
treatment of multidrug resistant infections.1,2 The 
added resistance conferred by biofilm development 
in such infections and the absence of novel 
antibiotics make polymyxins the drugs of choice, in 
spite of their nephrotoxicity and neurotoxicity.1,2,5  
Polymyxins are natural non-ribosomal cationic 
cyclic lipopeptides isolated from the bacterium 
Paenibacillus polymyxa.4 They  exert their 
antibacterial action by selectively binding to lipid A 
component of the lipopolysaccharide (LPS) and 
subsequently disrupt the outer membrane of Gram-
negative pathogens.3,6 
The effects of PMB and PMBN have been 
previously assessed on planktonic bacteria isolated 
















Aim of Study 
This study assessed the combined effects of cell-
membrane permeabilisers (PMB/PMBN) and two 
antibiotics (ceftazidime (CAZ) and levofloxacin 
(LEV) in an attempt to develop a strategy for biofilm 
disruption using the Minimum Biofilm Eradication 
Concentration Physiology and Genetic assay 




The MBEC P&G assay was carried out according 
to manufacturer’s instruction. Klebsiella 
pneumoniae (K. pneumoniae) and Proteus mirabilis 
(P. mirabilis) biofilms of initial broth suspensions of 
108 colony forming units per mL were cultivated on 
the pegs of the MBEC device overnight. They were 
subsequently challenged with 5120 µg/mL of both 
ceftazidime and levofloxacin in a ten-fold dilution 
assay in the presence of 100 and 500 µg/mL PMB 
and PMBN.  
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From the tables of results (Tables 1 and 2), it can 
be deduced that both ceftazidime and levofloxacin 
are very effective in inhibiting biofilm development 
(as shown by percentage inhibition (PI%)) when 
augmented with PMB and PMBN (Figures 1 and 2). 
This is about 100-fold increase in efficacy when 
compared to the antibiotics used on their own. The 
percentage reduction (PR%) in biofilm was also 
increased considerably when PMB and PMBN 
concentrations were increased to 500 µg/mL. PMB 
was more effective than its less antibacterial 
derivative PMBN. Levofloxacin was also found to 
be more effective than ceftazidime when combined 
with both PMB and PMBN due to its enhanced cell-
membrane permeability and as an anti-DNA 



























Though the polymyxins have proven to be the last 
resort in the treatment of multidrug resistant Gram-
negative pathogens, their nephrotoxicity and 
neurotoxicity have complicated their use.1,2,3,5,7  
Previous studies  have suggested the development 
of optimal dosage regimen with enhanced efficacy 
and reduced toxicity.5  However, this has not been 
possible as there is scanty knowledge on their 
pharmacology. Some Gram-negative pathogens 
have also developed resistance against polymyxins 
It has also been predicted that the combination of 
polymyxins with other antibiotics may reduce their 
side effects and resistance development.7 
In this study, the synergy between ceftazidime and 
levofloxacin and PMB and PMBN have suggested 
that effective combinations may provide alternate 
strategies towards biofilm eradication. 
Though the effective combinations used in this 
study yielded about 90% inhibition and 70% 
reduction in biofilms, they were above their therapy 
range. 
It has been suggested that modulation of the amino 
acid groups and the hydrophobic regions of PMB 
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Table 1. MBEC (µg/mL) and MIC (µg/mL) of ceftazidime and levofloxacin 
against  K. pneumoniae and P. mirabilis in the presence of PMB. 
a (PI) – Percentage (%) inhibition of biofilm at 100 and 500 µgm/mL MIC 
respectively 
b (PR) – Percentage (%) reduction of biofilm at 100 and 500 µgm/mL 
MBEC respectively. 
Figure 2. Molecular modelling of PMB-LPS and PMBN-LPS complexes 















PMBK.p* 100 500 100 500 73 90 24 35 
Ceftazidime 39.94 19.97 640 640 90 90 50 >60 
Levofloxacin 39.94 9.98 640 640 >90 >90 >50 >70 
 
P. mirabilis 
PMBP.m** 100 500 100 500 29 77 10 26 
Ceftazidime 9.98 19.87 640 320 70 >70 50 60 

















PMBNK.p 100 500 100 500 60 77 22 30 
Ceftazidime 39.94 19.97 640 640 >70 >80 50 >50 
Levofloxacin 39.94 9.98 640 640 60 95 70 >70 
 
P. mirabilis 
PMBNP.m 100 500 100 500 25 62 9 25 
Ceftazidime 9.98 19.97 640 320 60 >60 30 >40 
Levofloxacin 9.98 9.98 640 320 >90 >95 50 >60 
 
Table 2. MBEC (µg/mL) and MIC (µg/mL) of ceftazidime and levofloxacin 
against  K. pneumoniae and P. mirabilis in the presence of PMBN. 
*K.p – Klebsiella pneumoniae   **P.m – Proteus mirabilis 
 
Figure 1. Percentage inhibition (PI%) and percentage reduction (PR%) of K. 
pneumoniae and P. mirabilis biofilms in the presence of 100 and 500 µg/mL 
PMBK.p only and in combination with ceftazidime and levofloxacin 
respectively. 
Figure 2. Percentage inhibition (PI%) and percentage reduction (PR%) of K. 
pneumoniae and P. mirabilis biofilms in the presence of 100 and 500 µg/mL 
PMBNK.p only and in combination with ceftazidime and levofloxacin respectively. 
This work was financially supported by the University of Westminster 
and The Society for General Microbiology. 
